| Title: | Summary: Barr Pharmaceuticals Inc. |
| Price: | $175.00 |
| Publication Date: | May 01, 2008 |
| Report Type: | Summary |
| Abstract: | The low investment-grade rating on Woodcliff Lake, N.J.-based Barr Pharmaceuticals Inc. reflects its strong position in the growing generic drug industry, continued free cash flows, and its established conservative financial policies. These factors are somewhat mitigated by the high level of competition in the company's core generic drug and oral contraceptives markets. Barr's size and scale, exposure to faster-growing international generic drug markets, productive product pipeline, and solid higher-margin proprietary specialty drug franchises make it one of the better positioned players in the growing generic drug industry. The estimated $75 billion global generic drug industry is highly competitive, with relatively low barriers to entry and fierce, commodity-like price competition. Standard&Poor's Ratings Services expects the industry to grow at |
| Brief Excerpt: | RESEARCH Ratings Definitions Summary: Barr Pharmaceuticals Inc. Publication date: ##-May-#### Primary Credit Analyst: Arthur Wong, New York (#) ###-###-####; arthur_wong@standardandpoors.com Credit Rating: ###-/Stable/-- Rationale... |
| Word Count: | 1043 |
| Ticker: | BRL |
| Issuer: | Barr Pharmaceuticals Inc. |
| GICS: | Pharmaceuticals (35202010) |
| Sector: | Global Issuers, Corporations, Health Care |
| Country: | United States |
| Region: | United States |
| Format: | 
HTML
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?
